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Hearing disability is one of the world’s major health 
problems.[1] An estimated 360 million people currently 
live with disabling hearing loss (defined as hearing loss 
>40 dB in the better-hearing ear in adults (>15 years) 
and >30 dB in the better-hearing ear in children (0 - 14 
years).[2] The prevalence is greatest in the developing world, where the 
majority of deaf people reside.[1] Hearing loss is more common in adults 
than in children, constituting 91% of all cases.[2] The highest prevalence 
rates are found in sub-Saharan Africa (15.7%) and South Asia (17%).[1] 
Failure to deal with this health challenge perpetuates economic and health 
decline, as confirmed by the inverse relationship between the prevalence 
of hearing loss and gross national income.[2] For the individual, hearing 
loss leads to poor communication and social isolation.[3] The deaf are less 
likely to obtain employment than people with normal hearing, and those 
who are employed often earn incomes in the lowest bracket.[1,3]
Screening programmes directed at high-risk groups are necessary. 
If effective, they can reduce morbidity from hearing loss through 
early detection and rehabilitation.[4] Highly sensitive tools that yield 
lower false-positive and higher true-negative results are ideal for 
screening and monitoring hearing. There are currently few screening 
programmes for high-risk groups in the developing world.[5] High-risk 
groups include the elderly and patients receiving potentially ototoxic 
medications: chemotherapeutic agents,[6] second-line antituberculosis 
(TB) regimens and antiretrovirals (ARVs).[1,7,8] These groups are at 
risk of developing high-frequency hearing loss, as explained below.
High-risk groups
Presbycusis
Presbycusis (adult-onset hearing loss) is generally underdiagnosed 
and undertreated. This leads to late detection, disease progression 
and poor rehabilitation.[9,10] Such hearing loss is predominantly high 
frequency and sensorineural. Lin et al.[11,12] reported that older adults 
with hearing loss are more likely to develop cognitive impairment 
and dementia than their contemporaries without hearing loss. 
Regular monitoring and early detection and treatment of presbycusis 
would maintain an existing quality of life.
HIV and TB therapy
Currently approximately 25 million people in South Africa (SA) 
are HIV-positive.[13] Hearing loss can be caused by HIV and/or 
its treatment; both are implicated in sensorineural hearing loss.[7] 
Treatment aimed at opportunistic infections and antineoplastic 
therapy can have synergistic hearing effects on patients receiving 
ARVs.[7,8] TB therapy is one such treatment, and TB is an increasing 
problem in sub-Saharan Africa owing to co-infection with HIV. 
There are increasing numbers of cases of multidrug-resistant 
(MDR) TB in SA,[8,14] the treatment of which involves injectable 
aminoglycosides that are known to cause ototoxicity[8,15] via a 
synergistic ototoxic effect together with ARVs on the outer hair cells 
of the cochlea, leading to high-frequency sensorineural hearing loss 
(HFSNHL).[15]
Chemotherapy
Cancer rates are increasing rapidly in the developing world.[16] 
Cisplatin, a commonly used antineoplastic drug, is known to cause 
irreversible dose-dependent ototoxicity[6,17] leading to HFSNHL. 
Noise exposure may result in a three-fold increased risk of hearing 
loss with cisplatin.[17,18]
Ototoxicity monitoring is aimed at preventing or minimising 
the progression of hearing loss through prospective hearing 
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assessments. It is the most reliable method of detecting ototoxicity 
prior to development of symptomatic hearing loss[19] and permits 
clinicians to counsel patients, possibly modify treatment regimens, 
and rehabilitate hearing. Three methods of testing can be utilised, 
namely conventional audiology, high-frequency audiometry (HFA) 
and otoacoustic emissions. HFA has significant change criteria and 
excellent specificity and sensitivity,[8,19] but is generally not available 
in developing countries.
Advances in screening techniques
While screening programmes traditionally involve audiologists 
testing patients in soundproof booths, alternative screening 
methods have evolved in recent years. Telehealth projects allow 
patients in remote areas to be tested using high-speed internet.[20] 
Portable audiometers are also becoming more advanced, and 
provide good-quality diagnostic audiometry in any environmental 
setting.[21]
Global mobile phone penetration of the world’s population 
is at 85%,[22] and 1 in 5 Africans own smartphones. Automated 
hearing screening apps, using commercially available technology, 
present an opportunity to address the global problem of hearing 
loss. Yeung et al.[23] from the Children’s Hospital of Eastern 
Ontario reported on the first portable clinical ‘conditioned play’ 
iPad-based audiometer for the paediatric population. Their study 
shows promise in focusing on the shortcomings of existing play 
audiometry. Other authors have reported on the Apple uHear app 
using an iPodTouch device, with varying results. uHear is a hearing 
program devised by Unitron and Apple for use on any touch-
interface Apple device, and is freely available for download from 
the iTunes Apple store.
Szudek et al.[24] were the first of three groups to evaluate this 
app as a potential hearing screening tool. Using an iPodTouch, 
participants were tested in different noise level environments. 
Pure-tone averages (PTAs) calculated as a mean at thresholds 
of 500, 1 000, 2 000 and 4 000 Hz from the uHear application 
were compared with the formal audiogram. uHear was able to 
correctly diagnose the presence of moderate or worse hearing 
loss (PTA >40 dB) in 100 participants, with a sensitivity of 98% 
and a specificity of 82% in the clinic. In the soundproof room, 
sensitivity improved to 100% and specificity to 90%. Khoza-
Shangase et al.[25] sampled a group of children using the uHear 
application on an iPodTouch in a school environment. PTAs 
(mean at thresholds of 500, 1 000 and 2 000 Hz) from the uHear 
test were compared with PTAs from formal audiograms. They 
reported large deviations in the lower frequencies, standard 
deviations of >10 dB at individual thresholds and a 34% increased 
pick-up rate of hearing loss. The third study, by Handzel 
et al.,[26] tested participants with unilateral sudden sensorineural 
hearing loss using the uHear on an iPodTouch, and reported a 
sensitivity of 76% and a specificity of 91% when compared with 
a formal audiogram. Inaccurately elevated thresholds at low 
frequencies using uHear were also detected, corroborating the 
findings of the previous study.[25] Interestingly, uHear reflected 
hearing thresholds more accurately in mid- to high frequencies 
than in low ones, and deviations in low frequencies were less 
pronounced in the abnormal-hearing (diseased) ear. These two 
observations were also reported by Szudek et al.[24] These studies 
have highlighted two important points. Firstly, it is possible to 
rule out moderate or disabling hearing loss.[24,26] Secondly, even 
though low frequencies may be inaccurately elevated,[24-26] the 
degree of hearing loss in the participant with abnormal hearing 
can possibly be predicted in the high frequencies.[24,26]
Objectives
To determine the accuracy of: (i) the iPhone using the uHear app as a 
screening tool for moderate or worse hearing loss (PTA >40 dB), where 
PTA is the mean at thresholds of 500, 1 000, 2 000 and 4 000 Hz; and 
(ii) individual thresholds at certain frequencies, especially the 
high frequencies (which may be of use in high-risk population 
groups).
Methods
The study was approved by the Research Ethics Committee, Faculty 
of Health Sciences, University of Cape Town, SA. The design 
was quasi-experimental. Study participants were consecutively 
recruited from patients attending the Otolaryngology Clinic at 
Groote Schuur Hospital, Cape Town. The inclusion criteria were 
age 15 - 80 years and having had a formal audiogram performed 
by a trained audiologist at Groote Schuur Hospital in the previous 
2 weeks. Exclusion criteria included otorrhoea, visual impairment, 
learning disability, and poor gross motor skills rendering the patient 
incapable of tapping the screen. Non-English-speaking patients 
were not excluded if they understood the instructions after the 
task had been explained to them. All participants gave informed 
consent. The results obtained from the iPhone testing did not affect 
treatment plans.
Test instruments
An iPhone 4 mobile device (iOS 4.2) was used. The uHear app 
(version 1.0) was downloaded from iTunes on to the device at 
no cost. The application allows users to test their pure-tone air-
conduction hearing sensitivity as well as speech in noise. For this 
study, participants completed only the hearing sensitivity test, which 
employs a 267 ms pulse duration, with a ‘10 dB down and 5 dB up’ 
approach. The time delay between tone presentations is randomised 
to prevent anticipation, and the lowest threshold with two positive 
responses of three excursions is recorded as the hearing sensitivity.
‘Earbud’ earphones that come standard with the device were 
used, and the buds were cleaned with an alcohol swab before and 
after every test in the presence of the participant. With reference to 
calibration, a single iPhone was used to test all participants. The same 
uHear application (version 1.0) was used for all participants tested. 
Ambient noise levels in three test environments were measured at 
regular intervals with the OMD G45 71-6229 Psio sound level meter, 
providing an adequate measure of quality control. Sound levels for 
the respective environment complied with the South African Bureau 
of Standards requirements for all three environments.
Technique
Otoscopic examination was performed to exclude otorrhoea and 
wax impaction. Infection control was maintained during testing. All 
participants had formal audiograms done, and were tested in three 
different settings with the iPhone, i.e. the waiting room (WR), a quiet 
room (QR) and the soundproof room (SR).
Instructions to participants
Participants were given the device and the earphones to insert. The 
uHear app was selected, earphone connectivity confirmed and the 
participant advised to ‘tap the screen when a sound is heard’. The 
programme plays a series of pure tones of varying levels so that a 
threshold can be determined. On hearing a sound, the participant 
was expected to follow the commands. The duration of the test is 6 
minutes. No audiologist is normally required, as the program is a self-
assessment one. However, as this was a formal study an investigator 
was present to ensure that the test was completed.
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Data analysis
For hearing screening, the presence or absence of moderate or worse 
hearing loss (PTA >40 dB) in each ear was determined by formal 
audiometry, as 40 dB is considered the critical hearing threshold for 
disabling hearing loss according to the World Health Organization, 
and warrants further investigation.
The iPhone uHear PTAs in all three settings were compared with 
the formal audiogram PTAs, where the PTA is calculated as a mean 
of thresholds (hearing in dB) at 500, 1 000, 2 000 and 4 000 Hz. These 
data were captured into 2 × 2 tables to calculate sensitivity, specificity 
and accuracy ratios.
Additionally, in view of the possibility for agreement by ‘chance’, 
kappa analysis was performed on iPhone thresholds from all three 
settings when compared with the formal audiogram to detect 
agreement at all six frequencies. Kappa values range from <0.2 
to 1.0 depending on how well two thresholds correlate with each 
other at a particular frequency. The best correlation kappa value, 
i.e. ‘very good’, is one that is closest to 1. This describes how 
well the thresholds at a particular frequency correlated with the 
thresholds at the same frequency of the gold standard, the formal 
audiogram, and values this correlation according to the range 
described in Table 1.
Results
Thirty patients met the inclusion criteria and were recruited, of 
whom five were excluded for incomplete testing (unrelated to 
the device or software). Twenty-five patients were therefore fully 
tested (50 ears in total). Participants’ demographics are described 
in Table 2.
Accuracy of the iPhone uHear as a screening test. All ears with 
moderate or worse hearing loss (PTA >40 dB) were detected in all 
three settings. This translated to a sensitivity of 100%. Of the 42 
ears without moderate or worse hearing loss (PTA ≤40 dB), 15 had 
moderate or worse hearing in the WR (specificity 64%), 11 had 
moderate or worse hearing in the QR (specificity 74%), and 5 had 
moderate or worse hearing loss in the SR (specificity 88%) (Table 3). 
Accuracy in the WR was calculated as 70%, that in the QR as 78% and 
that in the SR as 90%.
Accuracy of the iPhone uHear thresholds at all six frequencies. 
Kappa analysis compared the ‘agreement’ of the iPhone thresholds 
in all three rooms with the formal audiogram thresholds as reflected 
in Table 4. The iPhone was highly accurate at the high frequencies 
(2 000, 4 000 and 6  000 Hz), where there was ‘good’ and ‘very 
good’ correlation in the SR and QR (Table 4). This was found to be 
statistically significant (p<0.05). The iPhone did not correlate well 
at low frequencies in all three rooms, being ‘fair to moderate’ in the 
SR and ‘poor to moderate’ in the QR. The WR showed ‘poor to fair’ 
correlation at low frequencies and ‘moderate’ correlation at high 
frequencies.
The iPhone uHear therefore reflected thresholds more accurately in 
the mid- to high frequencies than in the low frequencies. Furthermore, 
the SR did not eliminate this low-frequency inaccuracy. These two 
salient findings correlate with all three studies reviewed.[24-26]
Discussion
Our study is one of the first to evaluate smartphone-assisted 
audiometry as a hearing screening tool for populations that currently 
have no access to formal audiometry. Results indicate that the iPhone 
uHear application is reasonably accurate at screening for moderate 
or worse (disabling) hearing loss. We found a sensitivity of 100%, 
with a very high negative predictive value, implying an ideal test for 
screening. The highest test accuracy (90%) was found in an SR, with 
a specificity of 88%, rendering the least false positives. This highlights 
the need for caution when testing in a WR setting.
Table 1. Kappa range of values and their correlation
Kappa values ‘Agreement’/comparison
<0.2 Poor
0.21 - 0.4 Fair
0.41 - 0.6 Moderate
0.61 - 0.8 Good
0.81 - 1.0 Very good
Table 2. Participants’ demographics and hearing loss (as 
graded by the ASHA degree of severity of hearing loss)
Participants, N 25
Age (years), mean (range) 43 (15 - 86)
Age distribution (years), n
15 - 20 4
21 - 40 7
41 - 60 6




Ears with PTA (dB), n
≤25 (normal) 24
26 - 40 (mild loss) 18
41 - 55 (moderate loss) 5
56 - 70 (moderate to severe loss) 2
71 - 90 (severe loss) 1
≥91 (profound loss) 0
ASHA = American Speech-Language-Hearing Association; PTA = pure-tone average. 
Table 3. Accuracy of the iPhone as a screening test in three 
different settings (WR, QR, SR), compared with the formal 
audiogram
Formal audiogram, n
iPhone, n PTA ≤40 dB PTA >40 dB
WR
PTA ≤40 dB 17 0
PTA >40 dB 25 8
QR
PTA ≤40 dB 31 0
PTA >40 dB 11 8
SR
PTA ≤40 dB 37 0
PTA >40 dB 5 8
PTA = pure-tone average; WR = waiting room; QR = quiet room; SR = soundproof room.
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The iPhone uHear application was found to be 
highly accurate for detecting high-frequency 
hearing loss in the QR and SR in patients 
with various levels of hearing. The iPhone 
uHear application could therefore be used to 
screen those at high risk of developing high-
frequency hearing loss through early detection 
of abnormal or worsening thresholds.
The iPhone uHear application is therefore 
an appropriate tool to screen for disabling 
hearing loss, and to detect high-frequency 
hearing loss in the abovementioned high-
risk groups in poorly resourced communities 
that have limited access to healthcare. In 
particular, it can be used to screen and 
monitor hearing in drug-related ototoxicity 
where high-frequency assessments of both 
conventional audiometry and HFA have a 
high degree of sensitivity to detect early 
change in hearing.[19]
In addition, uHear is a self-assessment 
application that is available free from iTunes 
for all Apple users and is downloadable to 
any Apple device with a touchscreen interface 
and speakers (includes iPhone, iPad and 
iPodTouch). The test is quick and easy to 
perform, and designed for use by people of any 
language, socioeconomic status and intellectual 
capacity. Patients who are bed-bound, isolated 
or too weak to travel to an audiology centre 
could benefit from a mobile, freely available 
self-assessment hearing screening test like this.
Study limitations
More participants with varying degrees 
of hearing loss would possibly yield 
more accurate positive and negative 
predictive values, thereby rendering the 
testing more accurate. Environmental 
noise may have been a cause for poor 
results at the lower frequencies. Testing 
can possibly be improved by using 
background noise eliminators. Inset 
earphones are theoretically recommended 
as an effective way to reduce ambient 
noise. Being placed within the external 
ear canal, they can provide 30 - 40 dB 
attenuation of ambient noise.[27] In our 
study, inaccuracy can be related to 
insertion depth; ‘earbud’ earphones sit just 
beyond the concha at the entrance to the 
external ear canal, which could explain the 
poor low-frequency outcomes. In future, 
testing that incorporates inset earphones 
cupped by circumaural ear covers with 
integrated ambient noise level monitoring 
that eliminates or adjusts testing to 
accommodate background noise could be 
done. Although this would be ideal, it does 
counter the intention to screen using a 
device with its standard hardware. A single 
iPhone device was used for this study; to 
avoid problems relating to inter-device 
reliability, every iPhone may have to be 
calibrated.
Conclusions
The sensitivity of the uHear app used with 
the iPhone is adequate to screen for disabling 
hearing loss, and has good accuracy to 
high-frequency hearing loss in SRs and 
QRs. Early detection of hearing loss with 
hearing screening programmes is therefore 
possible using mobile digital technology. A 
mobile, non-operator-dependent method 
used to screen for disabling hearing loss 
and detect early high-frequency threshold 
changes, such as an Apple iPhone, can help 
overcome the lack of trained audiologists 
or available infrastructure in developing 
countries.[5] Because of the portability 
of the device, hearing screening with 
the iPhone uHear test is taken directly 
to the patient and is an opportune way 
to utilise existing community health and 
educational facilities. Oncology units, ARV 
rollout centres and TB hospitals with MDR/
extensively drug-resistant patients are ideal 
centres in which to use this technology. 
In addition, satellite clinics that regularly 
dispense chronic medication to older adults 
can also be considered.
Disclaimer. The Division of Otorhino-
laryngology, Groote Schuur Hospital, and the 
authors do not have any affiliation to the Apple 
or Unitron companies.
Table 4. Kappa values (range of values and their correlation are set out in Table 1) seen 
with iPhone and formal audiogram thresholds in three different settings (WR, QR, SR) 
Formal audiogram, low frequencies (Hz)
iPhone,
low frequencies (Hz) 250 500 1 000
WR
250 –0.0516 0.2217 0.4123 
500 0.0044 0.2399 0.4997
1 000 –0.0693 0.2526 0.5126
QR
250 –0.0101 0.2751 0.5677
500 0.0134 0.3102 0.5113
1 000 –0.0239 0.212 0.5207
SR
250 0.097 0.5309 0.4386
500 0.1309 0.5283 0.5316
1 000 0.0113 0.481 0.66 (p=0.000)
Formal audiogram, high frequencies (Hz)
iPhone,
high frequencies (Hz) 2 000 4 000 6 000
WR
2 000 0.496 0.663 0.4261
4 000 0.4667 0.339 0.5529
6 000 0.484 0.187 0.517
QR
2 000 0.73 (p=0.001) 0.5122 0.5535
4 000 0.4471 0.74 (p=0.000) 0.69 (p=0.000)
6 000 0.4339 0.69 (p=0.0092) 0.79 (p=0.0026)
SR
2 000 0.75 (p=0.000) 0.72 (p=0.0039) 0.69 (p=0.005)
4 000 0.73 (p=0.000) 0.85 (p=0.000) 0.89 (p=0.000)
6 000 0.77 (p=0.007) 0.92 (p=0.0010) 0.94 (p=0.000)
WR = waiting room; QR = quiet room; SR = soundproof room.
*In the ‘good’ and ‘very good’ correlation values (Table 1), p-values of <0.05 imply good statistical significance (figures in brackets).
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